[July 20, 2017]

Global Axial Spondyloarthritis (axSpA) Market and Forecasts Report 2017-2024 - Research and Markets

The "Axial spondyloarthritis (axSpA) Market and Forecast Analyst to 2024" report has been added to Research and Markets' offering.

The etiology of axSpA remains unclear, the condition is inheritable and genetics play a major role, with mutations in certain genes, including the human leukocyte antigen B27 gene, known to be associated with an increased risk of developing AS.

The initial signs and symptoms of the disease, including spinal pain and stiffness, are not specific to axSpA, therefore there is often a lag time between onset and diagnosis.

Studies suggest that axSpA is most prevalent in Caucasian populations and AS is typically more common in male adults, whereas nr-axSpA occurs more frequently in females.

Furthermore, axSpA is often associated with a series of extra-articular manifestations and co-morbidities, including uveitis, cardiovascular risk, and inflammatory bowel disease. As a result, direct medical spending on the diagnosis and treatment of these conditions intensifies axSpA's economic impact.

Key Topics Covered:

• Cimzia (certolizumab)
• Cosentyx (secukinumab)
• Enbrel (etanercept)
• Humira (adalimumab)
• Remicade (infliximab)
• Simponi (golimumab)
• Stelara (ustekinumab)
• Taltz (ixekizumab)

2. Treatment: Axial Spondyloarthritis

• Executive Summary
• Disease Definition and Diagnosis
• Current Treatment Options
• Prescribing Trends
• Compliance
• Treatment Challenges and Unmet Needs
• Impact of Pipeline Agents
• Impact of Biosimilars

3. Epidemiology: Axial Spondyloarthritis in the US, Japan, and 5EU

• Executive Summary
• Disease Background
• Sources and Methodology
• Forecast: Ankylosing Spondylitis
• Forecast: Non-Radiographic Axial Spondyloarthritis
• Forecast: Axial Spondyloarthritis
• Epidemiologist Insight
• Strengths and Limitations
• Appendix: Additional Sources

4. Marketed Drugs: Axial Spondyloarthritis

• Product profile: Cimzia
• Product profile: Cosentyx
• Product profile: Enbrel
• Product profile: Humira
• Product profile: Remicade
• Product profile: Simponi

5. Pipeline: Axial Spondyloarthritis

• Executive Summary
• Clinical Pipeline Overview
• Key Opinion Leader Research
• Product profile (late stage): Otezla
• Product profile (late stage): Stelara
• Product profile (late stage): Taltz

For more information about this report visit https://www.researchandmarkets.com/research/vfh26v/axial

View source version on businesswire.com: http://www.businesswire.com/news/home/20170720005728/en/

[ Back To TMCnet.com's Homepage ]